Types of inter-atomic interactions at the MHC-peptide interface: Identifying commonality from accumulated data

Hock Adrian, Png Eak; Rajaseger, Ganapathy; Mathura, Venkatarajan Subramanian; Sakharkar, Meena Kishore; Kangueane, Pandjassarame
January 2002
BMC Structural Biology;2002, Vol. 2, p2
Academic Journal
Background: Quantitative information on the types of inter-atomic interactions at the MHC-peptide interface will provide insights to backbone/sidechain atom preference during binding. Qualitative descriptions of such interactions in each complex have been documented by protein crystallographers. However, no comprehensive report is available to account for the common types of inter-atomic interactions in a set of MHC-peptide complexes characterized by variation in MHC allele and peptide sequence. The available x-ray crystallography data for these complexes in the Protein Databank (PDB) provides an opportunity to identify the prevalent types of such interactions at the binding interface. Results: We calculated the percentage distributions of four types of interactions at varying inter-atomic distances. The mean percentage distribution for these interactions and their standard deviation about the mean distribution is presented. The prevalence of SS and SB interactions at the MHC-peptide interface is shown in this study. SB is clearly dominant at an inter-atomic distance of 3Ã…. Conclusion: The prevalently dominant SB interactions at the interface suggest the importance of peptide backbone conformation during MHC-peptide binding. Currently, available algorithms are developed for protein sidechain prediction upon fixed backbone template. This study shows the preference of backbone atoms in MHC-peptide binding and hence emphasizes the need for accurate peptide backbone prediction in quantitative MHC-peptide binding calculations.


Related Articles

  • HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Guce, Abigail I; Mortimer, Sarah E; Yoon, Taejin; Painter, Corrie A; Jiang, Wei; Mellins, Elizabeth D; Stern, Lawrence J // Nature Structural & Molecular Biology;Jan2013, Vol. 20 Issue 1, p90 

    Mammalian class II major histocompatibility (MHCII) proteins bind peptide antigens in endosomal compartments of antigen-presenting cells. The nonclassical MHCII protein HLA-DM chaperones peptide-free MHCII, protecting it against inactivation, and catalyzes peptide exchange on loaded MHCII....

  • Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Claus Lundegaard; Ole Lund; Morten Nielsen // Bioinformatics;Jun2008, Vol. 24 Issue 11, p1397 

    Summary: Several accurate prediction systems have been developed for prediction of class I major histocompatibility complex (MHC):peptide binding. Most of these are trained on binding affinity data of primarily 9mer peptides. Here, we show how prediction methods trained on 9mer data can be used...

  • Antigen presentation: Revealing hidden peptides. Honey, Karen // Nature Reviews Immunology;Oct2003, Vol. 3 Issue 10, p774 

    Discusses research being done on the constitutive display of cryptic translation products by major histocompatibility complex (MHC) class I molecules. Reference to a study by S. Schwab et al., published in the 2003 issue of "Science"; Presentation of peptides derived from the 3' untranslated...

  • Crystal gazing. Clayton, Julie; Anderson, Alun; Knight, Jonathan; Webb, Jeremy; Jordan, Ruth; Wingerson, Lois; Liebmann, John; Greig, Vivienne; Kingsland, James; LePage, Michael; Kiser, Barbara; McCabe, Kirsty // New Scientist;04/15/2000, Vol. 166 Issue 2234, Special section p14 

    Focuses on the work of Pamela Bjorkman concerning major histocompatability complex (MHC) molecules which trigger immune reactions against foreign organisms. Need for new techniques such as cryo-electron microscopy; Use and shortcomings of X-ray crystallography; Other molecules which behave like...

  • MHC and MHC-Like Molecules in the Design of Vaccines. Apostolopoulos, Vasso // Current Pharmaceutical Design;10/1/2009, Vol. 15 Issue 28, p3207 

    The article discusses various reports published within the issue, including one on predicting peptides which bind to major histocompatibility complex (MHC), another on the characterization of peptides that bind to MHC based on tumor vaccines, and one on the role of MHC class II in vaccine design.

  • A geometric and algebraic view of MHC-peptide complexes and their binding properties. Cano, Pedro; Bo Fan // BMC Structural Biology;2001, Vol. 1, p2 

    Background: Major histocompatibility complex (MHC) molecules present peptides to T lymphocytes. It is of critical biological and medical importance to elucidate how different MHC alleles bind to a specific set of peptides. Method: In this study we approach the problem from the algebraic and...

  • Prediction of MHC class I binding peptides, using SVMHC. Dönnes, Pierre; Elofsson, Arne // BMC Bioinformatics;2002, Vol. 3, p25 

    Background: T-cells are key players in regulating a specific immune response. Activation of cytotoxic T-cells requires recognition of specific peptides bound to Major Histocompatibility Complex (MHC) class I molecules. MHC-peptide complexes are potential tools for diagnosis and treatment of...

  • Cloning and expression of three peptide-linked β2-microglobulin molecules in Escherichia coli with an isocaudamer technique. Fanyan Meng; Chuanlai Shen; Yong He; Fengqin Miao; Jianqiong Zhang // Biotechnology Letters;Jun2009, Vol. 31 Issue 6, p831 

    The application of the peptide-linked β2-microglobulin (β2m) strategy is limited in some cases due to the incompatibility between the sequences of the peptides and the restriction sites of the plasmid vectors. An isocaudamer technique was adapted to overcome this restriction. Three...

  • Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Hogan, Kevin T.; Sutton, Jennifer N.; Chu, Kyo U.; Busby, Jennifer A. C.; Shabanowitz, Jeffrey; Hunt, Donald F.; Slingluff Jr., Craig L. // Cancer Immunology, Immunotherapy;Apr2005, Vol. 54 Issue 4, p359 

    The development of peptide-based vaccines that are useful in the therapeutic treatment of melanoma and other cancers ultimately requires the identification of a sufficient number of antigenic peptides so that most individuals, regardless of their major histocompatibility complex (MHC)-encoded...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics